Physician profile
Gregory Desimone
NPI 1851785687
$765.51
in general payments reported to CMS, 2019-2025
13 companies · $26.68 in 2025
The $26.68 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.52 · 2020: $168 · 2021: $188 · 2022: $354 · 2025: $26.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $26.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $26.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.64 | 2019-2022 | |
| Novo Nordisk INC | $159.66 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $105.97 | 2020-2022 | |
| Pfizer INC. | $65.40 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.08 | 2022 | |
| Viiv Healthcare Company | $40.50 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.83 | 2022 | |
| Janssen Pharmaceuticals, INC | $30.72 | 2021-2022 | |
| Dexcom, INC. | $26.68 | 2025 | Dexcom G6 Transmitter |
| Ethicon US, LLC | $17.63 | 2021 | |
| Astellas Pharma US INC | $13.55 | 2022 | |
| Amgen INC. | $12.62 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Desimone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.